Insider · CIK 0001695076
Pivotal bioVenture Partners Fund I, L.P.
Files at EVMN (Evommune, Inc.). First filing -, latest -.
In brief
Pivotal bioVenture Partners Fund I, L.P. files SEC Form 4 as director and 10% owner at EVMN (Evommune, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Pivotal bioVenture Partners Fund I, L.P. has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Common Stockindirect: See footnotes | +1,441,032 | - | - | 1,441,032 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Common Stockindirect: See footnotes | +1,632,441 | - | - | 1,632,441 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Common Stockindirect: See footnotes | +294,502 | - | - | 294,502 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series Seed Preferred Stockderivativeindirect: See footnotes | -7,145,647 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series Seed Preferred Stockderivativeindirect: See footnotes | -3,572,816 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -2,582,243 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,230,283 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,895,260 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,104,740 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -313,571 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -313,571 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -2,508,575 | - | - | 0 | Nov 12, 2025 |
Questions about Pivotal bioVenture Partners Fund I, L.P.
Answered from the filings on this page, as of the latest one.
Is Pivotal bioVenture Partners Fund I, L.P. buying or selling?
Pivotal bioVenture Partners Fund I, L.P. has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Pivotal bioVenture Partners Fund I, L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Pivotal bioVenture Partners Fund I, L.P. has 0.
Where does Pivotal bioVenture Partners Fund I, L.P. file Form 4?
Pivotal bioVenture Partners Fund I, L.P. has filed Form 4 at EVMN (Evommune, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.